Brokerages predict that Moleculin Biotech Inc (NASDAQ:MBRX) will post ($0.09) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Moleculin Biotech’s earnings. Moleculin Biotech reported earnings per share of ($0.20) during the same quarter last year, which would suggest a positive year-over-year growth rate of 55%. The business is scheduled to announce its next quarterly earnings results on Monday, August 12th.
On average, analysts expect that Moleculin Biotech will report full-year earnings of ($0.37) per share for the current financial year. Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that follow Moleculin Biotech.
Moleculin Biotech (NASDAQ:MBRX) last issued its earnings results on Monday, May 13th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.09) by ($0.05).
A number of large investors have recently made changes to their positions in MBRX. Bank of New York Mellon Corp bought a new stake in Moleculin Biotech during the fourth quarter worth approximately $36,000. Northern Trust Corp raised its holdings in Moleculin Biotech by 109.1% during the fourth quarter. Northern Trust Corp now owns 47,918 shares of the company’s stock worth $50,000 after purchasing an additional 25,000 shares in the last quarter. BB&T Corp raised its holdings in Moleculin Biotech by 55.6% during the first quarter. BB&T Corp now owns 140,000 shares of the company’s stock worth $113,000 after purchasing an additional 50,000 shares in the last quarter. Finally, Taylor Cottrill Erickson & Associates Inc. raised its holdings in Moleculin Biotech by 24.6% during the first quarter. Taylor Cottrill Erickson & Associates Inc. now owns 151,781 shares of the company’s stock worth $123,000 after purchasing an additional 30,000 shares in the last quarter. 4.85% of the stock is currently owned by hedge funds and other institutional investors.
Shares of MBRX traded up $0.04 during mid-day trading on Thursday, reaching $1.26. 216,272 shares of the company’s stock traded hands, compared to its average volume of 1,925,669. The firm’s 50-day simple moving average is $1.21. The company has a market cap of $56.04 million, a PE ratio of -2.48 and a beta of 2.04. The company has a quick ratio of 1.49, a current ratio of 1.49 and a debt-to-equity ratio of 0.01. Moleculin Biotech has a 12 month low of $0.78 and a 12 month high of $3.15.
About Moleculin Biotech
Moleculin Biotech, Inc, a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company also develops WP1066 Portfolio, an immuno-stimulating STAT3 inhibitor for the treatment of brain tumors, pancreatic cancer, and AML; and WP1122 Portfolio and related molecules for the treatment of glioblastoma multiforme and related central nervous system malignancies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.